Skip to content
Screener

Aquestive Therapeutics, Inc. AQST Debt-to-equity

Debt-to-equity at other companies

ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
1.6×+1.6×
Viatris logo
ViatrisVTRS
1×0.0×
AbbVie logo
AbbVieABBV
46.6×+38.6×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
0×0.0×
Regenxbio logo
RegenxbioRGNX
1×+0.6×
Absci Corporation logo
Absci CorporationABSI
0×0.0×

Other financials

Income statement

See full
Revenue$13.8M+38.1%
Gross profit$9.8M+80.1%
Operating income-$8.2M+27.7%
Net income-$22.9M-68.8%
EPS (diluted)-$0.18-28.6%

Balance sheet

See full
Cash & equivalents$98.5M+62.7%
Total debt$63.4M+6.0%
Total equity-$56.6M+22.0%
Total assets$132.1M+41.0%

Cash flow

See full
Operating cash flow-$9.4M-19.3%
CapEx$212.0K+98.1%
Free cash flow-$9.7M-20.3%

Valuation

See full
Market cap$494.34M+28.9%
Enterprise value$459.23M+20.0%
P/S9.1×+0.5×

Profitability

See full
Gross margin67%+5.9pp
Operating margin-97.5%-15.0pp
Net margin-144.6%-2.6pp
FCF margin-85%-17.0pp

Returns & leverage

See full
Return on equity121.1%—
Current ratio7.2×+3.7×